Please try another search
For the six months ended 30 June 2019, Alder Biopharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 5% to $179.1M. Lower net loss reflects Research and Development decrease of 18% to $103.7M (expense), Change in fair value of derivative liabi decrease of 24% to $1.1M (expense), Interest Income increase of 7% to $4.5M (income).
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -55.76 | -114.09 | -77.42 | -58.48 |
Net Income | -58.41 | -117.93 | -80.09 | -60.92 |
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Total Assets | 462.57 | 513.17 | 426.24 | 496.75 |
Total Liabilities | 245.72 | 252.36 | 212.51 | 211.63 |
Total Equity | 216.85 | 260.81 | 213.73 | 285.13 |
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -133.87 | -74.58 | -250.85 | -178 |
Cash From Investing Activities | 0.23 | -28.04 | -121.12 | -181.32 |
Cash From Financing Activities | 160.5 | 159.74 | 377.94 | 376.83 |
Net Change in Cash | 26.85 | 57.13 | 5.97 | 17.51 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review